Management of Structural Coronary Microvascular Disease

Medication Optimization

The American College of Cardiology recommends uptitrating carvedilol to target doses (typically 12.5-25 mg twice daily) to achieve a resting heart rate of 55-60 bpm, as this vasodilating beta-blocker directly reduces minimal coronary resistance and increases diastolic perfusion time 1, 2
Consider switching from carvedilol to ivabradine if uptitration is limited by blood pressure, as head-to-head trials demonstrate ivabradine's superiority over bisoprolol in improving coronary collateral flow and CFR in microvascular angina patients, despite achieving similar heart rate reduction 1, 2
Optimize ACE inhibitor therapy, as ACE inhibitors improve endothelium-dependent vasodilation and reduce left ventricular stiffness, particularly important given the patient's diffuse atherosclerosis 1
Ensure aggressive statin therapy continuation, as statins improve endothelial function beyond lipid-lowering through anti-inflammatory mechanisms that directly benefit microvascular dysfunction 1

A coronary flow reserve (CFR) of 2.2 is considered abnormal, indicating inability to increase coronary flow above 2.2 times resting flow, and is a specific parameter defining impaired coronary vascular reserve 1, 3, 4
An index of microvascular resistance (IMR) of 32 is considered abnormal, indicating increased structural resistance in the coronary microcirculation, likely related to diffuse atherosclerosis causing microvascular remodeling, endothelial dysfunction, and reduced capillary density 3, 5

Repeat invasive coronary function testing (CFR and IMR) at 3-6 months after medication optimization to objectively measure improvement in coronary vascular reserve 1, 3, 4
Target CFR improvement to ≥2.5 and IMR reduction to <25 as objective endpoints 3, 4

Consider tricyclic antidepressants for enhanced pain perception, as 20-30% of patients remain symptomatic despite traditional antianginal therapy 1, 2
Adenosine antagonists represent an alternative for patients with enhanced pain perception 2

Implement aggressive smoking cessation, as cardiovascular risk factors significantly impair microvascular function and directly reduce coronary vascular reserve 1
Target weight loss if overweight/obese, as weight reduction improves endothelial function and microvascular remodeling 1

The European Society of Cardiology recommends nebivolol as a first-line antianginal therapy for patients with coronary microvascular disease (CMD) and elevated index of microcirculatory resistance (IMR), due to its ability to improve coronary flow reserve (CFR) by 24-33% 6, 7, 8
The American Heart Association suggests that nebivolol's mechanism of action involves beta-1 selective blockade and nitric oxide-mediated vasodilation, which reduces microcirculatory resistance and improves endothelial function 6, 7

The American College of Cardiology recommends starting nebivolol 5 mg once daily as first-line antianginal therapy for patients with documented IMR ≥25 units and CFR <2.0 without vasospastic component, and combining it with ACE inhibitor therapy to improve endothelium-dependent vasodilation 7, 8
The European Society of Cardiology advises targeting a resting heart rate of 55-60 beats per minute to maximize diastolic perfusion time, and considering repeat invasive coronary function testing at 3-6 months to objectively measure IMR reduction 6, 7

The American Heart Association warns that nebivolol is absolutely contraindicated in patients with vasospastic angina, as beta-blockade can precipitate coronary spasm, and recommends acetylcholine provocation testing to rule out vasospastic angina before initiating beta-blocker therapy 6, 7, 9
The European Society of Cardiology suggests that ivabradine may offer superior benefits in CMD by improving coronary collateral flow and CFR more effectively than bisoprolol, and can be considered as an alternative therapy when beta-blocker uptitration is limited by hypotension 7, 8